1. Damiani, G, Conic, RRZ, de Vita, V, et al. When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol Ther 2019; 32: e12793.
Google Scholar | Crossref2. Blauvelt, A, Papp, KA, Griffiths, CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo-and active comparator–controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405–417.
Google Scholar | Crossref | Medline3. Gordon, K, Blauvelt, A, Foley, P, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2018; 178: 132–139.
Google Scholar | Crossref | Medline4. Reich, K, Armstrong, AW, Foley, P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo-and active comparator–controlled voyage 2 trial. J Am Acad Dermatol 2017; 76: 418–431.
Google Scholar | Medline5. Langley, R, Tsai, TF, Flavin, S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 2018; 178: 114–123.
Google Scholar | Crossref | Medline6. Ger, TY, Huang, YH, Hui, RCy, et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis 2019; 10: 2040622319843756.
Google Scholar7. Chen, YC, Huang, YT, Yang, CC, et al. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan. PLoS ONE 2020; 15: e0244620.
Google Scholar | Crossref8. Fougerousse, AC, Ghislain, PD, Reguiai, Z, et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol 2020; 34: e644–e646.
Google Scholar | Crossref9. Laws, P, Downs, A, Parslew, R, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland. Br J Dermatol 2012; 166: 189–195.
Google Scholar | Crossref | Medline10. Galluzzo, M, Talamonti, M, De Simone, C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther 2018; 18: 727–735.
Google Scholar | Crossref | Medline11. Notario, J, Deza, G, Vilarrasa, E, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat 2019; 30: 424–429.
Google Scholar | Crossref | Medline12. Lin, PT, Wang, SH, Chi, CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep 2018; 8: 16068.
Google Scholar | Crossref | Medline13. Zweegers, J, Roosenboom, B, van de Kerkhof, P, et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol 2017; 176: 786–793.
Google Scholar | Crossref | Medline14. Huang, YW, Tsai, TF. Efficacy of tofacitinib in patients with moderate-to-severe psoriasis who had inadequate responses to prior biologics. Dermatol Sin 2019; 37: 205.
Google Scholar15. Benhadou, F, Ghislain, PD, Guiot, F, et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol 2020; 34: e837–e839.
Google Scholar | Crossref | Medline16. Galluzzo, M, Tofani, L, Lombardo, P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med 2020; 9: 2170.
Google Scholar | Crossref | Medline17. Ruggiero, A, Fabbrocini, G, Cinelli, E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther 2021; 34: e14673.
Google Scholar | Crossref18. Bonifati, C, Morrone, A, Cristaudo, A, et al. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther 2020; 34: e14584.
Google Scholar | Medline19. Papp, K, Crowley, J, Rubel, D, et al. Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: results from the VOYAGE 1 and 2 trials: 6729. J Am Acad Dermatol 2018; 79: AB87.
Google Scholar20. Reich, K, Armstrong, AW, Langley, RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019; 394: 831–839.
Google Scholar | Crossref | Medline21. Rodriguez Fernandez-Freire, L, Galán-Gutierrez, M, Armario-Hita, JC, et al. Short-term effectiveness and safety in real clinical practice. Dermatol Ther 2020; 33: e13344.
Google Scholar22. Armstrong, A, Blauvelt, A, Flavin, S, et al. Guselkumab demonstrates greater efficacy compared to secukinumab across body weight quartiles and body mass index categories: week 48 results from the ECLIPSE trial. 2. In: Proceedings of the 28th EADV congress, Madrid, Spain, , pp. 9–13.
Google Scholar23. Owczarczyk-Saczonek, A, Placek, W. Compounds of psoriasis with obesity and overweight. Postepy Hig Med Dosw 2017; 71: 761–772.
Google Scholar | Crossref24. Clark, L, Lebwohl, M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443–446.
Google Scholar | Crossref | Medline25. Brownstone, ND, Hong, J, Mosca, M, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics 2021; 15: 39–51.
Google Scholar | Medline26. Giunta, A, Babino, G, Ruzzetti, M, et al. Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: a retrospective study. J Int Med Res 2016; 44(Suppl. 1): 72–75.
Google Scholar | SAGE Journals27. Edson-Heredia, E, Sterling, KL, Alatorre, CI, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol 2014; 134: 18–23.
Google Scholar | Crossref | Medline28. Umezawa, Y, Saeki, H, Nakagawa, H. Some clinical factors affecting quality of the response to ustekinumab for psoriasis. J Dermatol 2014; 41: 690–696.
Google Scholar | Crossref | Medline29. Daien, CI, Morel, J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm 2014; 2014: 386148.
Google Scholar | Crossref | Medline30. Mourad, A, Straube, S, Armijo-Olivo, S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2019; 181: 450–458.
Google Scholar | Crossref | Medline31. Pinter, A, Gerdes, S, Papavassilis, C, et al. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat 2020; 31: 769–775.
Google Scholar | Crossref | Medline32. Puig, L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007–1011.
Google Scholar | Crossref | Medline33. Naldi, L, Addis, A, Chimenti, S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Dermatology 2008; 217: 365–373.
Google Scholar | Crossref | Medline34. Yao, Z, Hu, C, Zhu, Y, et al. Population pharmacokinetic modeling of guselkumab, a human IgG1λ monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2018; 58: 613–627.
Google Scholar | Crossref | Medline35. Tsai, YC, Tsai, TF. Switching biologics in psoriasis-practical guidance and evidence to support. Expert Rev Clin Pharmacol 2020; 13: 493–503.
Google Scholar | Crossref | Medline36. Wang, TS, Tsai, TF. Biologics switch in psoriasis. Immunother 2019; 11: 531–541.
Google Scholar | Crossref | Medline37. Damiani, G, Cazzaniga, S, Conic, RR, et al. Pruritus characteristics in a large Italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol 2019; 33: 1316–1324.
Google Scholar | Crossref | Medline38. Damiani, G, Bragazzi, NL, Garbarino, S, et al. Psoriatic and psoriatic arthritis patients with and without jet-lag: does it matter for disease severity scores? Insights and implications from a pilot, prospective study. Chronobiol Int 2019; 36: 1733–1740.
Google Scholar | Crossref | Medline39. Kocic, H, Damiani, G, Stamenkovic, B, et al. Dietary compounds as potential modulators of microRNA expression in psoriasis. Ther Adv Chronic Dis 2019; 10: 2040622319864805.
Google Scholar | SAGE Journals